Eli Lilly Return on Investment 1986-2025 | LLY

Current and historical return on investment (ROI) values for Eli Lilly (LLY) over the last 10 years.
Eli Lilly ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2025-06-30 $16.80B $52.53B 35.55%
2025-03-31 $14.09B $50.35B 32.40%
2024-12-31 $12.90B $42.80B 32.05%
2024-09-30 $10.43B $43.37B 28.30%
2024-06-30 $9.50B $37.37B 28.51%
2024-03-31 $7.47B $37.46B 23.88%
2023-12-31 $6.46B $29.19B 21.91%
2023-09-30 $8.88B $29.23B 31.10%
2023-06-30 $7.13B $29.31B 26.10%
2023-03-31 $6.22B $30.18B 24.06%
2022-12-31 $7.13B $25.51B 29.15%
2022-09-30 $7.21B $24.31B 29.79%
2022-06-30 $7.41B $23.35B 30.90%
2022-03-31 $7.61B $24.62B 32.36%
2021-12-31 $6.36B $24.50B 27.43%
2021-09-30 $6.43B $23.48B 28.40%
2021-06-30 $5.83B $21.40B 26.36%
2021-03-31 $5.62B $23.30B 26.03%
2020-12-31 $6.06B $22.41B 30.19%
2020-09-30 $5.47B $21.33B 29.40%
2020-06-30 $5.62B $19.34B 32.04%
2020-03-31 $5.92B $17.18B 35.14%
2019-12-31 $4.97B $16.52B 29.97%
2019-09-30 $4.47B $17.13B 25.57%
2019-06-30 $4.39B $16.58B 22.30%
2019-03-31 $2.88B $16.18B 13.91%
2018-12-31 $3.53B $20.11B 15.58%
2018-09-30 $2.91B $25.83B 12.64%
2018-06-30 $2.11B $20.79B 9.26%
2018-03-31 $3.32B $23.98B 14.04%
2017-12-31 $2.00B $21.61B 8.69%
2017-09-30 $2.40B $24.89B 10.33%
2017-06-30 $2.81B $24.04B 12.13%
2017-03-31 $2.53B $21.74B 11.01%
2016-12-31 $3.26B $22.45B 14.09%
2016-09-30 $2.91B $24.32B 12.56%
2016-06-30 $2.93B $23.34B 12.77%
2016-03-31 $2.88B $22.51B 12.65%
2015-12-31 $2.69B $22.56B 11.83%
2015-09-30 $2.67B $23.31B 11.99%
2015-06-30 $2.31B $22.69B 10.40%
2015-03-31 $2.32B $22.36B 10.38%
2014-12-31 $2.66B $20.72B 11.74%
2014-09-30 $3.23B $22.98B 14.09%
2014-06-30 $4.18B $23.30B 18.58%
2014-03-31 $4.79B $23.60B 22.26%
2013-12-31 $5.37B $21.84B 26.23%
2013-09-30 $5.50B $21.16B 27.39%
2013-06-30 $5.10B $19.53B 25.25%
2013-03-31 $4.80B $19.39B 23.67%
2012-12-31 $4.73B $20.29B 23.12%
2012-09-30 $4.72B $21.57B 23.40%
2012-06-30 $5.16B $19.81B 25.95%
2012-03-31 $5.55B $20.23B 28.02%
2011-12-31 $5.53B $19.00B 28.33%
2011-09-30 $5.87B $20.51B 30.02%
2011-06-30 $6.04B $19.48B 31.32%
2011-03-31 $6.23B $19.07B 33.35%
2010-12-31 $6.53B $19.18B 35.89%
2010-09-30 $5.75B $19.39B 32.94%
2010-06-30 $5.68B $17.10B 33.87%
2010-03-31 $5.49B $17.12B 33.70%
2009-12-31 $5.59B $16.16B 35.65%
2009-09-30 $1.86B $16.68B 12.86%
2009-06-30 $1.60B $15.25B 10.82%
2009-03-31 $1.27B $14.60B 8.01%
2008-12-31 $0.69B $11.35B 4.07%
2008-09-30 $4.99B $17.93B 26.64%
2008-06-30 $4.77B $19.28B 25.65%
2008-03-31 $4.44B $19.56B 24.89%
2007-12-31 $4.06B $18.10B 23.91%
2007-09-30 $4.00B $17.48B 24.89%
2007-06-30 $3.84B $16.13B 23.84%
2007-03-31 $3.91B $16.16B 23.76%
2006-12-31 $4.13B $14.48B 24.68%
2006-09-30 $4.05B $17.61B 23.49%
2006-06-30 $3.93B $17.51B 22.93%
2006-03-31 $3.83B $17.31B 23.26%
2005-12-31 $3.65B $16.56B 22.63%
2005-09-30 $3.61B $17.26B 22.81%
2005-06-30 $3.54B $14.71B 22.89%
2005-03-31 $3.56B $15.96B 23.27%
2004-12-31 $3.27B $15.41B 21.66%
2004-09-30 $3.21B $15.82B 21.64%
2004-06-30 $3.28B $14.03B 22.59%
2004-03-31 $3.23B $15.06B 22.45%
2003-12-31 $3.50B $14.45B 25.02%
2003-09-30 $3.51B $14.48B 25.88%
2003-06-30 $3.39B $13.55B 25.90%
2003-03-31 $3.32B $13.51B 26.53%
2002-12-31 $3.25B $12.63B 27.28%
2002-09-30 $3.04B $12.63B 26.93%
2002-06-30 $3.03B $11.25B 28.17%
2002-03-31 $3.29B $11.08B 31.73%
2001-12-31 $3.54B $10.24B 35.70%
2001-09-30 $3.77B $10.52B 39.59%
2001-06-30 $3.98B $9.66B 43.73%
2001-03-31 $3.76B $9.25B 42.88%
2000-12-31 $3.56B $8.68B 41.52%
2000-09-30 $3.61B $8.85B 43.16%
2000-06-30 $3.49B $8.31B 43.27%
2000-03-31 $3.40B $8.44B 44.82%
1999-12-31 $3.36B $7.83B 46.75%
1999-09-30 $3.64B $7.68B 52.78%
1999-06-30 $3.52B $6.43B 52.86%
1999-03-31 $3.43B $6.84B 50.41%
1998-12-31 $3.41B $6.62B 49.59%
1998-09-30 $2.64B $6.78B 38.00%
1998-06-30 $2.50B $6.95B 35.99%
1998-03-31 $2.41B $7.13B 34.40%
1997-12-31 $2.31B $6.97B 30.87%
1997-09-30 $2.37B $6.74B 30.00%
1997-06-30 $2.27B $7.17B 27.09%
1997-03-31 $2.16B $9.08B 24.80%
1996-12-31 $2.05B $8.62B 23.99%
1996-09-30 $1.96B $8.61B 23.40%
1996-06-30 $1.93B $8.48B 23.77%
1996-03-31 $1.95B $8.42B 24.29%
1995-12-31 $1.98B $8.03B 25.44%
1995-09-30 $1.95B $7.60B 25.45%
1995-06-30 $1.92B $8.08B 25.98%
1995-03-31 $2.22B $7.47B 31.95%
1994-12-31 $2.13B $7.48B 32.61%
1994-09-30 $2.15B $6.49B 35.87%
1994-06-30 $2.09B $6.32B 34.93%
1994-03-31 $1.79B $5.80B 30.09%
1993-12-31 $1.83B $5.40B 30.47%
1993-09-30 $1.87B $6.41B 31.11%
1993-06-30 $1.67B $6.14B 28.94%
1993-03-31 $1.65B $6.00B 28.79%
1992-12-31 $1.72B $5.47B 30.38%
1992-09-30 $1.66B $5.44B 29.50%
1992-06-30 $1.86B $6.00B 33.12%
1992-03-31 $1.85B $5.75B 34.27%
1991-12-31 $1.77B $5.36B 34.02%
1991-09-30 $1.72B $5.36B 35.89%
1991-06-30 $1.68B $5.15B 38.22%
1991-03-31 $1.61B $4.92B 38.74%
1990-12-31 $1.54B $3.75B 38.42%
1990-09-30 $1.37B $3.74B 33.49%
1990-06-30 $1.25B $4.17B 30.28%
1990-03-31 $1.19B $4.37B 29.44%
1989-12-31 $1.16B $4.03B 29.74%
1989-09-30 $1.07B $3.95B 28.01%
1989-06-30 $1.05B $3.86B 28.24%
1989-03-31 $1.00B $3.82B 27.46%
1988-12-31 $0.92B $3.61B 25.81%
1988-09-30 $0.64B $3.57B 18.28%
1988-06-30 $0.63B $3.53B 18.13%
1988-03-31 $0.61B $3.57B 17.93%
1987-12-31 $0.58B $3.41B 17.32%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12